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Objective: The objective of this study was to assess the long-term safety of linezolid in 
patients with chronic infections requiring treatment for $6 weeks. Enhanced monitoring for 
optic neuropathy was included to characterize the early development of this side effect and to 
identify ophthalmologic tests that might be valuable in early detection of this event.
Methods: This was a multicenter, open-label, pilot study of patients aged $18 years on 
long-term linezolid therapy. Matched control patients were included for baseline assessment 
comparison. Patients were assessed at study entry, monthly while on treatment, at the end of 
treatment, and 30 days following the last dose. Aggregate ocular safety data were reviewed. 
Response to treatment was reported.
Results: The study was terminated owing to slow enrollment. Twenty-four patients received 
linezolid; nine patients were included as matched controls. Linezolid was prescribed for a median 
of 80.5 days (range, 50–254 days). In patients with a reported clinical outcome, the majority 
were considered improved or cured. Common treatment-related adverse events (AEs) included 
anemia, peripheral neuropathy, polyneuropathy, vomiting, and asthenia, and were consistent 
with the known safety profile. Most AEs resolved or stabilized with discontinuation of treatment. 
Results of ophthalmologic tests in the one case adjudicated as probable linezolid-associated 
optic neuropathy revealed abnormal color vision, characteristic changes in the optic disk, and 
central scotomas in each eye.
Conclusion: In our small population, linezolid was generally well tolerated and AEs were con-
sistent with the known safety profile. Extensive ophthalmologic testing of all 24 linezolid-treated 
patients identified one case adjudicated as probable, linezolid-associated optic neuropathy.
Keywords: linezolid, oxazolidinones, optic nerve diseases, peripheral nervous system 
diseases, safety
Introduction
Linezolid is a synthetic oxazolidinone antibiotic, active against gram-positive bacteria.1 
The antibacterial effect of linezolid comes from the inhibition of the 50S subunit of 
the bacterial ribosome. In the US and Europe, linezolid is approved for the treatment 
of nosocomial pneumonia, community-acquired pneumonia, complicated skin, and 
skin structure infections caused by susceptible gram-positive bacteria, including 
methicillin-resistant Staphylococcus aureus.1,2 Additionally, US-only indications 
include uncomplicated skin and skin structure infections and vancomycin-resistant 
Enterococcus faecium infections.1 Recommended duration of treatment varies 
(10–28 days) with the type of infection being targeted. In clinical practice, linezolid 
has been used for a longer duration in difficult-to-treat infections.3–5 The safety and 
efficacy of linezolid, when given for .28 days, have not been evaluated in controlled 
clinical trials.
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In clinical studies, the most common adverse reactions 
reported in patients treated with linezolid include diarrhea, 
vomiting, headache, nausea, and anemia. Myelosuppression, 
optic neuropathy, and peripheral neuropathy have also been 
reported. In general, spontaneous reports of optic and periph-
eral neuropathies in patients receiving linezolid have occurred 
when patients received treatment extending beyond the 
approved maximum 28 days of treatment,1,2,6–8 yet occurrences 
associated with shorter term use have also been reported.8,9 
The clinical presentation of optic neuropathy is similar to that 
seen with toxic, metabolic, drug-related, Cuban epidemic, and 
hereditary optic neuropathies; these syndromes have been 
attributed to abnormalities in mitochondrial transport and 
defective mitochondrial placement along the neuron.10,11 Optic 
and peripheral neuropathies described with linezolid have been 
reported as symmetrical and progressive.8,9,12,13 The neuropa-
thies may become permanent, with optic neuropathy resulting 
in a loss of vision with continued therapy. Some visual recov-
ery is reported following treatment discontinuation.13
A study was undertaken to prospectively assess the 
overall long-term safety of linezolid in patients with chronic 
infections who required treatment with 600 mg every 12 hours 
for $6 weeks. The study included enhanced monitoring 
for optic neuropathy in an attempt to characterize the early 
development of this side effect and to identify ophthalmologic 
tests that might be valuable in early detection of this event.
Patients were closely monitored for development of 
peripheral and optic neuropathies as well as for bone marrow 
suppression and lactic acidosis.
Materials and methods
This multicenter, open-label, pilot study was conducted at six 
recruiting centers in the US and three centers in Europe between 
17 November, 2008, and 27 December 2013. ClinicalTrials.
gov: NCT00359632. The study, and protocol and informed 
consent documentation were reviewed and approved by 
the following: Henry Ford Health Systems Institutional 
Review Board (Detroit, MI, USA), Regionala Etikprövn-
ingsnämnden i Stockholm (Stockholm, Sweden), Western 
Institutional Review Board (Olympia, WA, USA), St Ber-
nards Medical Center Institutional Review Board (Jonesboro, 
AR, USA), Ochsner Clinic Foundation Institutional Review 
Board (New Orleans, LA, USA), Conitato Etico Azienda 
Ospedaliero Universitaria San Martino (Genova, Italy), and 
the Research Subjects Protection Program (Minneapolis, MN, 
USA). Written informed consent was provided by all patients 
prior to participation in the study. This study was conducted 
in compliance with the ethical principles originating in or 
derived from the Declaration of Helsinki and in compliance 
with all the International Conference on Harmonization 
(ICH) Good Clinical Practice (GCP) Guidelines and all local 
regulatory requirements.
Study patients
Patients considered for study enrollment were $18 years 
old, required long-term antibiotic therapy, and had received 
linezolid 600 mg every 12 hours for 6 weeks or longer and 
were currently on drug (or had received linezolid for 6 weeks 
or longer and discontinued use within 7 days of baseline 
evaluation). Use of any medication, including antibiotics, 
with a known potential to produce ocular or neurologic 
toxicity indistinguishable from linezolid-associated toxicity, 
was not permitted. Control patients individually matched 
to linezolid-treated patients were included if they had been 
treated with antibiotics other than linezolid for $6 weeks and 
had similar infection diagnoses (based on anatomical site and 
chronicity), duration of treatment, and demographics (age 
and sex). Data collected from control patients were limited to 
baseline assessments. This was not a parallel-group study.
Duration of linezolid therapy while on the study was at 
the investigator’s discretion based on the benefit and risks of 
continued therapy. Patients of childbearing potential were to 
use a highly effective method of contraception throughout the 
study and for at least 28 days after the last dose of therapy. 
Patients were excluded from the study if they were pregnant 
or nursing; had known optic nerve damage or significant 
peripheral nerve damage unrelated to linezolid; had a pre-
existing ophthalmologic condition that would affect study 
testing (eg, dense cataracts, macular degeneration, congenital 
color vision deficiency, nystagmus, high myopia, and retinitis 
pigmentosa); had significant exposure or anticipated exposure 
to medications known to cause optic neuropathy or peripheral 
neuropathy; had deficiency states which may cause optic neu-
ropathy; or had lactic acidosis, or a condition, or were on a 
medication, that causes lactic acidosis. Patients with an active 
communicable disease, severe liver disease, or other severe 
acute or chronic conditions were not permitted in the study.
Treatment
Once enrolled, patients continued receiving linezolid 600 mg 
orally or intravenously every 12 hours if considered medi-
cally necessary. Treatment could be discontinued at any point 
in the study (some patients may have discontinued therapy 
within the 7 days prior to baseline assessment). The decision 
to continue or discontinue linezolid treatment, if there was a 
clinical suspicion or evidence of linezolid-associated toxicity, 
was at the discretion of the treating physician. Patients were 
permitted to remain on study for a maximum of 1 year. The 
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study was terminated after 5 years due to slow enrollment. 
No patient received linezolid for .5 months.
Study visits
Study visits for the treatment group occurred at study entry 
(screening/baseline), monthly for the duration of therapy, 
at the end of treatment (within 7 days of last dose) and at the 
end of study (30 days after the last dose). At each visit, general 
medical history, vital sign measurement, neurological exami-
nation, clinical laboratory testing, ophthalmologic screening, 
and adverse event (AE) monitoring were conducted. Patients 
entering the study who had discontinued linezolid-use within 
7 days of baseline were assessed at a 1-month follow-up 
evaluation to ensure capture of any additional AEs occur-
ring after discontinuation. Patients in the control group were 
assessed and tested a single time for baseline data to identify 
the presence of background abnormalities.
assessments
Clinical outcome
Clinical outcome of the underlying infection was evaluated 
as a global assessment by the investigator. Response was 
categorized as cure (resolution of infection with no need 
for additional antimicrobials), improvement (improvement 
in two or more, but not all clinical signs and symptoms of 
disease with no additional treatment needed), failure (persis-
tence or progression of signs and symptoms of infection or 
development of new finding consistent with active infection), 
or unknown (inability to assess response).
Safety
Clinical laboratory testing included assessment of blood chem-
istry, electrolytes, hematology, vitamin B6, vitamin B12, and 
folate levels. If abnormalities related to hematologic changes 
or peripheral neuropathy were identified during the treatment 
period, patients were studied periodically after discontinuation 
of linezolid treatment to determine the natural history (resolu-
tion, progression, or persistence) of identified events.
A battery of ophthalmologic tests designed to identify 
and characterize early development of optic neuropathy 
were selected by an independent Ocular Safety Expert 
Committee (OSEC) consisting of ophthalmologists 
and neuro-ophthalmologists. These included Snellen 
best-corrected visual acuity, intraocular pressure (IOP), 
relative afferent pupillary defect, color test plates (Ishihara – 
14 plate series), color vision (Farnsworth D-28 Hue Test), 
contrast sensitivity (Pelli-Robson); Amsler grid (2- and 
3-dimensional), Humphrey visual field (24-2 SITA standard 
and test of foveal sensitivity), slit lamp examination, dilated 
funduscopic examination, nerve fiber layer thickness (optical 
coherence tomography-3), and stereo optic nerve head pho-
tograph (baseline only, secondary test for subsequent visits). 
If abnormalities suggestive of optic nerve toxicity were 
identified during screening testing, comprehensive neuro-
ophthalmologic testing was performed to determine the pres-
ence of optic neuropathy. The OSEC reviewed the aggregate 
ocular safety data on an ongoing basis. In addition, aggregate 
data were reviewed by the OSEC to correlate ophthalmologic 
screening test results with confirmed optic nerve toxicity.
Additional data were gathered to identify potential risk 
factors for development of ophthalmic and neuropathic tar-
get toxicities, including patient demographics, underlying 
comorbidities, concomitant medications, environmental 
factors, and mitochondrial genetics. The treating physician 
received all test results including ocular tests and made all 
decisions regarding treatment.
Clinical laboratory assessments were performed by 
Covance Clinical Laboratory Services, Inc., Indianapolis, 
IN, USA (for US centers), and Covance Central Laboratories, 
Geneva-CH, Switzerland (for centers in Europe).
adverse events
Investigators recorded all observed and volunteered AEs 
and their opinion of the relationship to linezolid or matched 
control. Adverse events included serious AEs (an AE that 
resulted in death, was life-threatening, required hospitaliza-
tion, resulted in persistent or significant disability/incapacity, 
or lack of efficacy for an approved indication), abnormal 
test findings, and clinically significant changes in physical 
examination findings.
Statistical analysis
A sample size of 30 patients per group (treated and control) 
was considered adequate to assess the study objectives (not 
based on statistical considerations). Descriptive statistics 
were used to summarize safety parameters and demographics. 
All enrolled patients were included in the safety analysis.
To aid in enrollment, the protocol was amended to reduce 
the minimum duration of prior linezolid treatment for study 
entry, from 8 weeks to 6 weeks.
Results
patient disposition and characteristics
The study was prematurely terminated after 5 years owing 
to slow enrollment; study results were limited by the small 
sample size.
Thirty-four patients were enrolled in the study; 24 patients 
received linezolid (16 were treated while on study and eight 
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were treated within 7 days prior to screening); one patient did 
not receive treatment and was not included in the safety analy-
ses; and nine patients were identified as matched controls and 
completed the baseline assessment. Twenty of the linezolid 
patients (20/24, 83.3%) completed the study. The nine con-
trol patients were well-matched to their respective linezolid 
counterparts; 1:1 matching of controls was not possible for 
all linezolid-treated patients with the early study termination. 
Two deaths were reported in patients treated with linezolid, 
neither death was considered related to treatment. One 
death was related to sepsis and the other to heart transplant 
rejection. Five patients (20.8%) permanently discontinued 
linezolid due to AEs considered related to treatment (anemia, 
n=2; peripheral neuropathy, n=1; peripheral neuropathy and 
retinal nerve fiber layer thickening, n=1; and polyneuropathy, 
n=1). With the exception of the mild retinal thickening, these 
AEs were considered moderate in severity.
Baseline characteristics for the linezolid and the nine 
matched control patients are presented in Table 1. The 
majority of patients were male and white with a mean age of 
53.4 years. The most common primary diagnoses in the 
linezolid group were device-related infections (n=11) and 
osteomyelitis (n=4). Bacterial arthritis (n=2), device-related 
infections (n=2), and osteomyelitis (n=3) were the most com-
mon primary infection in the nine matched control patients. 
The median duration of total linezolid treatment (pre- and 
post-study) was 80.5 days (range, 50–254 days). The median 
pre-enrollment treatment for the control group was 227 days 
(range, 60–1,877 days). Antibiotics used in the matched con-
trol patients included fluoroquinolones, sulfamethoxazole/
trimethoprim, daptomycin, and vancomycin. A list of the 
antibiotics with treatment durations and infection type for 
the control group is shown in Table 2. Linezolid infection 
type and treatment durations are listed in Table 3.
Clinical outcome
Successful long-term treatment with linezolid was reported. 
Clinical outcome was reported in 15 of the linezolid treated 
patients. At the end of treatment, most patients were 
considered improved (9/15, 60%). Additional outcomes 
reported included cure (1/15, 6.7%), improved with some 
symptoms (2/15, 13.3%), possibly cured (1/15, 6.7%), and 
failure (2/15, 13.3%). At the end of study, treatment was 
considered successful with majority of infections cured or 
Table 1 Baseline characteristics
Baseline characteristics Linezolid,  
N=24, n, %
Control,  
N=9, n, %
age, years, mean (SD) 53.4 (13.4) 50.1 (11.9)
Male, n (%) 14 (58.3) 6 (66.7)
White, n (%) 16 (66.7) 7 (77.8)
Weight, kg, mean (SD) 92.2 (22.8) 86.6 (17.9)
Body mass index, mg/kg/m2, mean (SD) 30.9 (8.9) 30.3 (3.7)
Abbreviation: SD, standard deviation.
Table 2 Control patient antibiotics #6 weeks of study entrya
Patient Infection Antibiotic Antibiotic  
duration (days)
1 osteomyelitis Ciprofloxacin 1,613+
Doxycycline 1,071+
2 osteomyelitis Cefadroxil 226+
Moxifloxacin 226+
3 osteomyelitis Cefepime 50
Ciprofloxacin 30+
Vancomycin 43
4 Staphylococcal infection Doxycycline 170
5 pseudomonal infection aztreonam 90+
Daptomycin 167+
6 Device-related infection Levofloxacin 93+
Rifampicin 93+
7 Bacterial arthritis penicillin 54
8 Device-related infection Sulfamethoxazole/ 
trimethoprim
319+
Rifampicin 110+
9 Bacterial arthritis Sulfamethoxazole/ 
trimethoprim
58
Levofloxacin 72+
Rifampicin 62
Notes: aother treatments may have been given for infection, which were 
discontinued .6 weeks from study entry; + treatment ongoing.
Table 3 linezolid-treated patients’ duration of treatment
Patient Infection Linezolid  
duration (days)
1 Wound infection 172
2 limb abscess 63
3 liver abscess 52
4 Device-related infection 78
5 Device-related infection 156
6 Device-related infection 76
7 Device-related infection 121
8 Device-related infection 77
9 Device-related infection 91
10 Device-related infection 74
11 Device-related infection 136
12 Device-related infection 60
13 Device-related infection 50
14 Device-related infection 58
15 Bacterial arthritis 125
16 osteomyelitis 83
17 osteomyelitis 91
18 osteomyelitis 189
19 osteomyelitis 50
20 Hidradenitis 254
21 abdominal wall infection 127
22 Septic arthritis 73
23 postoperative wound infection 146
24 postoperative wound infection 64
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improved (19/21, 90.5%). The small sample size prevented 
meaningful assessments comparing response rates across 
demographic or baseline characteristics.
General safety findings
As the control group patients were only included for baseline 
assessment, a direct comparison between the safety find-
ings reported with linezolid over the entire study period is 
not appropriate. The linezolid safety population included 
24 patients receiving linezolid for a median of 80.5 days.
Treatment-emergent aes
All treatment-emergent AEs are reported in Table 4. The most 
common AEs reported that were considered related to treatment 
included anemia (n=5, 20.8%), peripheral neuropathy (n=3, 
12.5%), polyneuropathy (n=3, 12.5%), vomiting (n=2, 8.3%), 
and asthenia (n=2, 8.3%). The remaining AEs occurred in no 
more than one patient (4.2%). Several AEs (pyrexia, muscular 
weakness, diarrhea, paresthesia, increased lactic acid, leukope-
nia, and neutropenia) were reported by a single patient. No cases 
of drug-induced liver injury were reported with linezolid.
In our population, anemia was reported between days 
44 and 136 of treatment; similarly, peripheral and polyneu-
ropathy were reported between days 47 and 91 and days 47 
and 146, respectively. Anemia resolved in the two patients 
who received blood transfusions and was still present at the 
end of study in those receiving no treatment beyond the dis-
continuation of linezolid. The cases of polyneuropathy and 
peripheral neuropathy were considered mild to moderate in 
severity. Additional treatment for these symptoms was given 
to some but not all patients, treatments included gabapentin, 
pregabalin, amitriptyline, and acetaminophen.
Table 4 Treatment-emergent aes reported with linezolida
Treatment-emergent 
AEs
Linezolid 
treatment related, 
N=24, n (%)
All 
causalities, 
N=24, n (%)
Blood and lymphatic system disorders
anemia 5 (20.8) 6 (25.0)
leukopenia 1 (4.2) 1 (4.2)
neutropenia 1 (4.2) 1 (4.2)
Sideroblastic anemia 1 (4.2) 1 (4.2)
eye disorders 
Diabetic retinal edema 1 (4.2)
optic neuropathy 1 (4.2) 1 (4.2)
Retinal disorder/retinal 
nerve fiber layer thickening
1 (4.2) 1 (4.2)
Toxic optic neuropathy 1 (4.2) 1 (4.2)
Visual impairment 1 (4.2)
Gastrointestinal disorders 
Upper abdominal pain 1 (4.2) 1 (4.2)
Diarrhea 1 (4.2) 1 (4.2)
Gastrointestinal disorder 1 (4.2) 2 (8.3)
nausea 1 (4.2) 3 (12.5)
Tooth discoloration 1 (4.2) 1 (4.2)
Vomiting 2 (8.3) 3 (12.5)
General disorder
asthenia 2 (8.3) 2 (8.3)
Chest pain 1 (4.2)
Fatigue 1 (4.2)
General physical health 
deterioration
1 (4.2) 1 (4.2)
Malaise 1 (4.2) 1 (4.2)
peripheral edema 1 (4.2)
pyrexia 1 (4.2)
infections 
Folliculitis 1 (4.2)
oral candidiasis 1 (4.2)
Sepsis 1 (4.2)
Vulvovaginal mycotic 
infection
1 (4.2) 1 (4.2)
(Continued)
Table 4 (Continued)
Linezolid 
treatment related, 
N=24, n (%)
All 
causalities, 
N=24, n (%)
Metabolism and nutrition disorders 
Decreased appetite 1 (4.2)
Folate deficiency 1 (4.2) 3 (12.5)
Malnutrition 1 (4.2)
Hyperkalemia 1 (4.2)
Vitamin B1 deficiency 2 (8.3)
Vitamin B12 deficiency 1 (4.2) 2 (8.3)
Vitamin B6 deficiency 1 (4.2) 2 (8.3)
Musculoskeletal disorder 
Musculoskeletal chest pain 1 (4.2)
nervous system disorder
Dysgeusia 1 (4.2) 1 (4.2)
Headache 1 (4.2) 1 (4.2)
peripheral neuropathy 3 (12.5) 3 (12.5)
paresthesia 1 (4.2) 1 (4.2)
polyneuropathy 3 (12.5) 3 (12.5)
Sinus headache 1 (4.2)
Somnolence 1 (4.2)
Respiratory disorder
Cough 1 (4.2)
Vascular disorder
Hypertension 1 (4.2)
other
Complications of 
transplant surgery
1 (4.2)
lactic acid increase 1 (4.2) 1 (4.2)
Hemoglobin decrease 1 (4.2)
Hepatic enzyme increase 1 (4.2)
platelet count increase 1 (4.2) 2 (8.3)
Total protein increase 1 (4.2)
Vitamin B1 decrease 1 (4.2) 1 (4.2)
Vitamin B12 decrease 1 (4.2)
Weight decrease 1 (4.2) 1 (4.2)
Note: aoccurred within 30 days of last date of linezolid administration.
Abbreviation: ae, adverse event.
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Five ocular events were reported in the linezolid group: 
optic neuropathy (n=2), toxic optic neuropathy, retinal 
nerve fiber thickening, diabetic retinal edema, and visual 
impairment (n=1 for each); one patient from the control 
group reported narrow anterior chamber angle. The ocular 
event was identified at baseline after linezolid had been dis-
continued in two patients (optic neuropathy and optic nerve 
toxicity) and during study treatment in three patients. Three 
of the cases of visual abnormalities (optic neuropathy [n=12], 
toxic optic neuropathy, and retinal nerve fiber thickening) 
were considered related to linezolid treatment by the inves-
tigator. The OSEC used visual testing results in conjunction 
with patient history to identify optic toxicity. A single case 
was adjudicated by the OSEC as probable optic neuropathy 
related to linezolid, and one additional case was adjudicated 
as possible optic neuropathy unrelated to linezolid. These 
cases are described subsequently.
oSeC adjudications
probable optic neuropathy related to linezolid
Diagnosed in a 39-year-old black female treated for a device-
related (central line) infection; received 145 days of linezolid 
prestudy exposure and 11 days of study exposure predomi-
nantly at 1,200 mg/d. The patient died on study day 38, from 
multiple causes not considered related to study drug. Initial 
examination completed on study day 1 showed: visual acuity 
of 20/20 right eye and 20/30 left eye, IOP measured 17 mmHg 
in each eye, no relative afferent pupillary defect, and 
markedly abnormal color vision (two of 14 plates correctly 
identified in each eye). The optic disks showed prominent 
surface telangiectatic vessels in both eyes without clear optic 
atrophy, and visual fields showed cecocentral scotomas each 
eye. Testing was negative for the three common mutations 
associated with Leber hereditary optic neuropathy. The optic 
neuropathy was considered consistent with linezolid use.
possible nonprogressive optic neuropathy and severe 
optic atrophy unrelated to linezolid
Diagnosed in a 57-year-old black male treated for a limb 
abscess and line infection; received 61 days of linezolid pre-
study exposure and 2 days of study exposure at 1,200 mg/d. 
Concurrent diagnoses included cataract, diabetic retinopathy, 
and glaucoma. Concomitant treatment for primary open 
angle glaucoma included topical Combigan® eye drops and 
oral acetazolamide. Initial examination showed: visual acu-
ity of 20/200 (right eye) and 20/15 (left eye), IOP measured 
22 mmHg (right eye) and 12 mmHg (left eye), and a rela-
tive afferent pupillary defect was present in the right eye. 
The optic disks showed severe glaucomatous excavation 
with moderate atrophy right eye, less severe glaucomatous 
excavation, and atrophy left eye, and visual fields showed 
severe generalized depression right eye with equivocal nasal 
defect left eye. The examination remained unchanged through 
the end of study visit. While there was clear evidence of optic 
neuropathy right eye and equivocal evidence left eye, the 
damage was considered unrelated to linezolid.
Serious aes
Six patients reported ten serious AEs: fever and sepsis 
(n=1), worsening hypertension (n=1), polyneuropathy (n=2), 
severe clinical impairment/general health deterioration with 
nausea, asthenia, weight loss, vomiting, increased lactate 
dehydrogenase (n=1), and increased lactate dehydrogenase 
(two separate events), sideroblastic anemia, and acute rejec-
tion of heart transplant (n=1). The investigators considered 
sideroblastic anemia, severe clinical impairment, and two 
cases of polyneuropathy related to linezolid. Recovery 
from polyneuropathy with continued peripheral neuropathy 
sequelae at 23 months postlinezolid exposure was reported 
in one patient with polyneuropathy; symptoms of bilateral 
foot neuropathy at 3 months postlinezolid discontinuation 
remained present in the second patient. Full recovery and 
resolution from sideroblastic anemia and severe clinical 
impairment were reported in the remaining two patients.
Discussion
To our knowledge, this is the first report of linezolid use 
in patients with infections requiring extended therapy that 
were closely followed up for safety outcomes in a clinical 
trial setting. This pilot study was designed to monitor AEs 
including optic and peripheral neuropathy associated with 
linezolid treatment for at least 6 weeks duration. In this study, 
the duration of linezolid treatment (median 80.5 days) was 
longer than the recommended durations in the approved indi-
cations (10–28 days) as reflected in the product labeling.1,2 
Positive clinical outcomes were reported in the majority 
of patients, and linezolid was generally well tolerated for 
the prolonged duration of exposure. In general, AEs were 
considered reversible.
Safety findings and AEs that were reported included neu-
ropathies and bone marrow suppression that were consistent 
with the known safety profile of linezolid.1,2 Interference with 
mitochondrial function, specifically oxidative phosphoryla-
tion has been postulated as the mechanism responsible for 
neuropathy and bone marrow suppressions with long-term 
use of linezolid.2,13,14 Because bacterial ribosomes and 
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long-term use of linezolid
mitochondrial ribosomes are homologous, drugs, such as 
linezolid, that inhibit bacterial protein synthesis often inhibit 
mitochondrial protein synthesis.10,11,15,16 The disruption of 
mitochondrial function may impede oxidative phosphoryla-
tion and adenosine triphosphate production.15
As part of the safety monitoring, a battery of ophthalmo-
logic tests were used to screen for abnormalities, and potential 
cases of optic neuropathy were adjudicated by an expert 
panel. Of the limited cases reviewed, results of the visual field 
testing, color plate testing, optic photographs, and optical 
coherence tomography were valuable for identification of 
possible toxicities in linezolid-treated patients. The combina-
tion of dyschromatopsia, symmetric cecocentral visual field 
loss, and optic disk surface vascular abnormalities is consis-
tent with a toxic/metabolic optic neuropathy. As previously 
discussed, mitochondrial dysfunction in retinal ganglion cells 
is the proposed mechanism of damage. As Leber hereditary 
optic neuropathy, an inherited mitochondrial disorder, pro-
duces similar, although more severe, visual loss, along with 
strikingly similar optic disk surface vascular telangiectasia, 
genetic testing helps differentiate the underlying cause.15,16 
It should be noted, however, that nutritional deficiency 
optic neuropathy produces similar patterns of optic nerve 
dysfunction, and occasional cases have demonstrated optic 
disk surface vascular telangiectasia.17
Patients in the control group were treated with several 
different antibiotics on a long-term basis including fluoro-
quinolones, doxycycline, daptomycin, and sulfamethoxazole/
trimethoprim. It is important to note that these agents, along 
with linezolid, are not without associated risks and their use 
in the treatment of chronic bacterial infections should be 
closely monitored. The decision to prescribe longer dura-
tions of therapy with these agents must be based on a careful 
assessment of benefit vs risk in each individual case.
The purpose of the study was to characterize safety in 
patients receiving $6 weeks of linezolid. AEs in patients 
receiving short-term treatment has been well studied and 
documented.1 Given that patients must have received and 
tolerated extended linezolid therapy for study inclusion, our 
study only reflects a population of patients able to tolerate 
linezolid for a period of $6 weeks. Early study termination 
and a smaller than desired sample size limits the interpretation 
of results. Insufficient data were collected as a result of the 
early study termination; data were insufficient to assess inci-
dence of or to characterize in detail optic nerve toxicities or to 
relate their occurrence to the duration of treatment, comorbid 
conditions, or other epidemiologic factors. Due to the study 
design, the control group was only monitored for AEs and 
safety at baseline and no postbaseline data were captured, 
thus, a direct comparison between the control and linezolid 
treatment groups is not possible. Although the clinical out-
comes of the infections were recorded, the study was not 
designed to draw conclusions regarding the efficacy.
In this close follow-up of a small number of patients 
receiving linezolid for extended periods of time, linezolid 
was well tolerated and the AEs were consistent with the 
known safety profile. The information gathered suggests 
that appropriate monitoring for the early detection of poten-
tial toxicities, such as use of appropriate ophthalmologic 
testing to identify optic neuropathy may be of value in the 
management of patients requiring treatment with linezolid 
that extends beyond the recommended duration. This is 
especially beneficial in cases of extreme medical need where 
therapeutic options are limited, and the benefits of continued 
therapy outweigh potential risks.
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